

**AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics
CME Approved Sessions Worksheet
October 11-15, 2023**

Date	Time	Session	Session Title	Approved Credits	Credits Claimed
Wednesday, October 11	2:00 p.m. - 3:30 p.m.	Educational Session 1	Patient Derived Models to Accelerate Drug Discovery	1.50	
	3:45 p.m. - 5:15 p.m.	Educational Session 2	Challenges and Prospects in the Analysis of Spatial and Single Cell Biology	1.50	
	5:45 p.m. - 7:20 p.m.	Keynote	Keynote Lectures	1.50	
			<i>Maximum Approved Credits for Oct. 11</i>	4.50	TOTAL:
Thursday, October 12	8:00 a.m. - 9:40 a.m.	Plenary Session 1	Liquid Biopsies in the Clinic: Is It Ready for Prime Time?	1.75	
	10:00 a.m. - 11:40 a.m.	Plenary Session 2	The Journey of Antibody Drug Conjugate Development	1.75	
	11:45 a.m. - 12:15 p.m.	Proffered Papers 1	Spotlight on Proffered Papers 1	0.50	
	4:00 p.m. - 5:40 p.m.	Concurrent Session 1	T-Cell Engaging Bispecific Antibodies in Solid Tumors	1.75	
		Concurrent Session 2	Killing Shapeshifting Tumors: Leveraging Plasticity to Target Tumor Heterogeneity		
		Concurrent Session 3	The Future of Tumor Agnostic Drug Development		
			<i>Maximum Approved Credits for Oct. 12</i>	5.75	TOTAL:
Friday, October 13	8:00 a.m. - 9:40 a.m.	Plenary Session 3	TBA	1.75	
	10:00 a.m. - 11:40 a.m.	Plenary Session 4	New Drugs on the Horizon	1.75	
	11:45 a.m. - 12:15 p.m.	Proffered Papers 2	Spotlight on Proffered Papers 2	0.50	
	4:00 p.m. - 5:40 p.m.	Concurrent Session 4	Targeting Stromal Cells in Cancer Immunotherapy	1.75	
		Concurrent Session 5	Large-Scale Multicenter Platform Trials: Combine and Conquer		
		Concurrent Session 6	Unmet Needs and Opportunities to Advance Therapies for Rare Cancers		
			<i>Maximum Approved Credits for Oct. 13</i>	5.75	TOTAL:

Saturday, October 14	8:00 a.m. - 9:40 a.m.	Plenary Session 5	Targeting the DNA Damage Response: Lessons from the Past, Looking into the Future	1.75	
	10:00 a.m. - 11:40 a.m.	Concurrent Session 7	Glyco-immunobiology in Cancer Drug Development	1.75	
		Concurrent Session 8	Targeted Immunotherapy Approaches against pp53		
		Concurrent Session 9	Advances in Targeted Protein Degradation and Induced Proximity		
	11:45 a.m. - 12:15 p.m.	Proffered Papers	Spotlight on Proffered Papers 3	0.50	
	4:00 p.m. - 5:40 p.m.	Concurrent Session 10	Next Generation Cytokine Engineering for Cancer	1.75	
		Concurrent Session 11	Emerging T Cell Checkpoints Beyond PD1, CTLA4, and LAG3		
		Concurrent Session 12	Drug Screening		
			<i>Maximum Approved Credits for Oct. 14</i>	5.75	TOTAL:
Sunday, October 15	8:00 a.m. - 9:40 a.m.	Plenary Session 6	Expanding the Frontiers of T Cell Therapy	1.75	
	10:00 a.m. - 11:40 a.m.	Plenary Session 7	NK Cell Therapeutics	1.75	
	12:00 p.m. - 1:40 p.m.	Plenary Session 8	Emerging Role of Therapeutic Vaccines and mRNA in Cancer	1.75	
			<i>Maximum Approved Credits for Oct. 15</i>	5.25	
			<i>Maximum CME Credits Approved</i>	27.00	TOTAL: